Neuromuscular block with doxacurium (BW A938U) in patients with normal or absent renal function
- PMID: 2138489
- DOI: 10.1093/bja/64.2.186
Neuromuscular block with doxacurium (BW A938U) in patients with normal or absent renal function
Abstract
The characteristics of neuromuscular block induced by doxacurium were compared in patients with and without renal function. Seventeen patients with end stage chronic renal failure and 18 patients with normal renal function were anaesthetized with 0.5% halothane and nitrous oxide in oxygen and received doxacurium in an initial dose of 25 micrograms kg-1 (estimated from available data as an ED95 dose), with incremental doses of 5 micrograms kg-1. At the end of surgery, residual neuromuscular block was antagonized with either edrophonium 1.0 mg kg-1 or neostigmine 0.08 mg kg-1. There was no significant difference between the mean maximum blocks achieved with doxacurium: 17.4% (renal failure group) and 11.6% (control group) of control twitch heights, or between the mean times to achieve maximum block (10.9 min and 10.8 min, respectively). The mean duration of action of doxacurium, indicated by the time for twitch height to recover to 25% of control, was longer in the renal failure group (120.8 min vs 66.7 min in the control group) (ns). Similarly, the mean duration of action of increments was longer in the renal failure group (27.4 min vs 20.5 min in the control group). The rate of spontaneous recovery from doxacurium as indicated by the time for twitch height to recover from 0 to 5%, 5 to 10% and 10 to 25%, was not significantly different in the two groups. Antagonism of doxacurium was achieved more reliably with neostigmine than with edrophonium in both groups. The administration of doxacurium was associated with minimal cardiovascular effects.
Similar articles
-
Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.Drugs. 1992 Aug;44(2):182-99. doi: 10.2165/00003495-199244020-00003. Drugs. 1992. PMID: 1382013 Review.
-
Doxacurium. A review of its pharmacology and clinical potential in anaesthesia.Drugs. 1991 Oct;42(4):673-89. doi: 10.2165/00003495-199142040-00009. Drugs. 1991. PMID: 1723368 Review.
-
Clinical pharmacology of doxacurium chloride. A new long-acting nondepolarizing muscle relaxant.Anesthesiology. 1988 Oct;69(4):478-86. doi: 10.1097/00000542-198810000-00006. Anesthesiology. 1988. PMID: 2972233 Clinical Trial.
-
Neuromuscular and cardiovascular effects of doxacurium in children anaesthetized with halothane.Br J Anaesth. 1989 Mar;62(3):263-8. doi: 10.1093/bja/62.3.263. Br J Anaesth. 1989. PMID: 2522789 Clinical Trial.
-
Reversal of doxacurium and pancuronium neuromuscular blockade with neostigmine in children.Can J Anaesth. 1994 Nov;41(11):1074-80. doi: 10.1007/BF03015657. Can J Anaesth. 1994. PMID: 7828255 Clinical Trial.
Cited by
-
Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.Pharm World Sci. 1997 Feb;19(1):13-34. doi: 10.1023/a:1008641427473. Pharm World Sci. 1997. PMID: 9089750 Review.
-
New developments in nondepolarizing muscle relaxants.Yale J Biol Med. 1993 Sep-Oct;66(5):463-71. Yale J Biol Med. 1993. PMID: 7825348 Free PMC article. Review.
-
Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.Drugs. 1992 Aug;44(2):182-99. doi: 10.2165/00003495-199244020-00003. Drugs. 1992. PMID: 1382013 Review.
-
Doxacurium. A review of its pharmacology and clinical potential in anaesthesia.Drugs. 1991 Oct;42(4):673-89. doi: 10.2165/00003495-199142040-00009. Drugs. 1991. PMID: 1723368 Review.
-
The use of muscle relaxants in the intensive care unit.Can J Anaesth. 1992 Nov;39(9):949-62. doi: 10.1007/BF03008345. Can J Anaesth. 1992. PMID: 1451224 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous